-
公开(公告)号：US20160317602A9
公开(公告)日：2016-11-03
申请号：US14676370
申请日：2015-04-01
Applicant: AbbVie Inc.
Inventor： Walid M. Awni , Barry M. Bernstein , Andrew L. Campbell , Sandeep Dutta , Chih-Wei Lin , Wei Liu , Rajeev M. Menon , Thomas J. Podsadecki , Tianli Wang
IPC: A61K38/06 , A61K31/7072 , A61K38/05
CPC classification number: A61K38/06 , A61K31/454 , A61K31/498 , A61K31/7072 , A61K38/05 , A61K2300/00
Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.
-
公开(公告)号：US08993578B2
公开(公告)日：2015-03-31
申请号：US14138449
申请日：2013-12-23
Applicant: AbbVie Inc.
Inventor： Barry M. Bernstein , Rajeev M. Menon , Amit Khatri , Sven Mensing , Sandeep Dutta , Daniel E. Cohen , Scott C. Brun , Walid M. Awni , Emily O. Dumas , Cheri E. Klein , Thomas J. Podsadecki
IPC: A61K31/4965 , A61K31/675 , A61K31/425 , A61K31/40 , A61K38/00 , A61K38/12 , A61K31/4025 , A61K31/513 , A61K31/473 , A61K31/4184 , A61K31/427 , A61K31/7072 , A61K38/06
CPC classification number: A61K38/07 , A61K31/4025 , A61K31/4184 , A61K31/427 , A61K31/473 , A61K31/513 , A61K31/7072 , A61K38/05 , A61K38/06 , A61K38/12 , A61K45/06 , G06F17/10 , G06F19/12
Abstract: The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to a subject an effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), and an inhibitor of cytochrome P450 (e.g., ritonavir).
Abstract translation: 本发明的特征在于用于治疗HCV的干扰素和不含利巴韦林的疗法。 优选地，治疗超过较短的治疗持续时间，例如不超过12周。 在一个方面，所述疗法包括向具有HCV感染的受试者施用至少两种没有干扰素和利巴韦林的直接作用的抗病毒剂。 例如，治疗包括向受试者施用有效量的治疗剂1，治疗剂2（或治疗剂3）和细胞色素P450（例如利托那韦）的抑制剂。
-
公开(公告)号：US08969357B2
公开(公告)日：2015-03-03
申请号：US14138515
申请日：2013-12-23
Applicant: AbbVie Inc.
Inventor： Barry M. Bernstein , Rajeev M. Menon , Amit Khatri , Sven Mensing , Sandeep Dutta , Daniel E. Cohen , Scott C. Brun , Walid M. Awni , Emily O. Dumas , Cheri E. Klein , Thomas J. Podsadecki
IPC: A61K31/4965 , A61K31/70 , A61K31/425 , A61K31/40 , A61K31/675 , A61K38/00 , A61K38/12 , A61K38/07 , A61K31/7056 , A61K31/402 , A61K31/4184 , A61K31/426 , A61K31/4709 , A61K31/497 , A61K31/513 , A61K45/06 , A61K31/427 , A61K38/05 , A61K31/4025 , A61K31/7072
CPC classification number: A61K38/07 , A61K31/402 , A61K31/4025 , A61K31/4184 , A61K31/426 , A61K31/427 , A61K31/4709 , A61K31/497 , A61K31/513 , A61K31/675 , A61K31/7056 , A61K31/7072 , A61K38/05 , A61K38/12 , A61K45/06 , A61K2300/00
Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), an inhibitor of cytochrome P450 (e.g., ritonavir), and ribavirin.
Abstract translation: 本发明的特征在于用于治疗HCV的无干扰素治疗。 优选地，治疗过程持续时间较短，例如不超过12周。 在一个方面，治疗方法包括向具有HCV感染的受试者施用至少两种直接作用的抗病毒剂和利巴韦林。 例如，治疗包括向受试者施用有效量的治疗剂1，治疗剂2（或治疗剂3），细胞色素P450抑制剂（例如利托那韦）和利巴韦林。
-
Patent Agency Ranking
公开(公告)号：US20150025000A1
公开(公告)日：2015-01-22
申请号：US14507157
申请日：2014-10-06
Applicant: AbbVie Inc.
Inventor： Barry M. Bernstein , Scott C. Brun
IPC: A61K31/7056 , A61K31/427 , A61K31/7068 , A61K38/07 , A61K45/06 , A61K31/497 , A61K31/7076
CPC classification number: A61K31/7056 , A61K31/4196 , A61K31/426 , A61K31/427 , A61K31/473 , A61K31/4965 , A61K31/497 , A61K31/7068 , A61K31/7076 , A61K38/07 , A61K45/06 , A61K2300/00
Abstract: The present invention features interferon-free therapies for the treatment of HCV. The therapies comprise administering 2R,6S,13aS,14aR,16aS,Z)-N-(cyclopropylsulfonyl)-6-(5-methylpyrazine-2-carboxamido)-5,16-dioxo-2-(phenanthridin-6-yloxy)-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-exadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a-carboxamide (Compound I), or a pharmaceutically acceptable salt thereof, and another anti-HCV agent. Preferably, the therapies are both interferon- and ribavirin-free. The other anti-HCV agent can be a HCV polymerase inhibitor, an HCV NS5A inhibitor, an HCV entry inhibitor, a cyclophilin inhibitor, or an internal ribosome entry site inhibitor. Preferably, the other anti-HCV agent is an HCV polymerase inhibitor. Also preferably, the other anti-HCV agent is an HCV NS5A inhibitor. Also preferably, the other anti-HCV agent is administered concurrently with Compound I or a pharmaceutically acceptable salt thereof. In another example, the other anti-HCV agent is administered sequentially with Compound I or a pharmaceutically acceptable salt thereof. In still another embodiment, Compound I (or a pharmaceutically acceptable salt thereof) is co-administered with two or more other anti-HCV agents. For instance, Compound I (or a pharmaceutically acceptable salt thereof) can be co-administered with an HCV polymerase inhibitor and an HCV NS5A inhibitor. For another instance, Compound I (or a pharmaceutically acceptable salt thereof) can be co-administered with two different HCV polymerase inhibitors (e.g., one is a nucleoside polymerase inhibitor and the other is a non-nucleoside polymerase inhibitor; or both are nucleoside polymerase inhibitors; or both are non-nucleoside polymerase inhibitor). In yet another example, Compound I (or a pharmaceutically acceptable salt thereof) is co-administered with another HCV protease inhibitor and an HCV polymerase inhibitor. In still another example, Compound I (or a pharmaceutically acceptable salt thereof) is administered with two different HCV NS5A inhibitors.
-
公开(公告)号：US20150011481A1
公开(公告)日：2015-01-08
申请号：US14320843
申请日：2014-07-01
Applicant: AbbVie Inc.
Inventor： Regis A. Vilchez , Lino X. Rodrigues, JR. , Barry M. Bernstein , Thomas J. Podsadecki , Scott C. Brun , Daniel E. Cohen , Rajeev M. Menon , Amit Khatri , Sven Mensing , Sandeep Dutta , Walid M. Awni , Emily O. Dumas , Cheri E. Klein , Tolga Baykal
IPC: A61K38/07 , A61K31/7056 , A61K31/427 , A61K38/05
CPC classification number: A61K31/427 , A61K31/4025 , A61K31/497 , A61K31/513 , A61K31/7056 , A61K2300/00
Abstract: The present invention features interferon-free therapies for treating HCV genotype 1b, 2, 3 or 4. In one aspect, the therapies comprise administering Compound 1, ritonavir, and Compound 2 to a subject infected with HCV genotype 1b or 4, wherein the therapies do not include administration of any interferon, and the therapies last for 12 weeks. Preferably, the therapies do not include administration of any ribavirin.
Abstract translation: 本发明具有用于治疗HCV基因型1b，2,3或4的无干扰素治疗。一方面，治疗方法包括向感染HCV基因型1b或4的受试者施用化合物1，利托那韦和化合物2，其中治疗 不包括任何干扰素的治疗，治疗持续12周。 优选地，所述疗法不包括施用任何利巴韦林。
-
公开(公告)号：US20140323395A1
公开(公告)日：2014-10-30
申请号：US14330495
申请日：2014-07-14
Applicant: AbbVie Inc.
Inventor： Barry M. Bernstein , Rajeev M. Menon , Amit Khatri , Sven Mensing , Sandeep Dutta , Daniel E. Cohen , Thomas J. Podsadecki , Scott C. Brun , Walid M. Awni , Emily O. Dumas , Cheri E. Klein
IPC: A61K38/07 , A61K31/427 , A61K38/05
CPC classification number: A61K38/07 , A61K31/4025 , A61K31/4178 , A61K31/4196 , A61K31/427 , A61K31/4709 , A61K31/4725 , A61K31/473 , A61K31/501 , A61K31/513 , A61K31/5377 , A61K31/7072 , A61K38/05 , A61K45/06 , A61K2300/00
Abstract: The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to a subject an effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), and an inhibitor of cytochrome P450 (e.g., ritonavir).
Abstract translation: 本发明的特征在于用于治疗HCV的干扰素和不含利巴韦林的疗法。 优选地，治疗超过较短的治疗持续时间，例如不超过12周。 在一个方面，所述疗法包括向具有HCV感染的受试者施用至少两种没有干扰素和利巴韦林的直接作用的抗病毒剂。 例如，治疗包括向受试者施用有效量的治疗剂1，治疗剂2（或治疗剂3）和细胞色素P450（例如利托那韦）的抑制剂。
-
公开(公告)号：US08680048B2
公开(公告)日：2014-03-25
申请号：US13656012
申请日：2012-10-19
Applicant: AbbVie Inc.
Inventor： Barry M. Bernstein , Rajeev M. Menon , Amit Khatri , Sven Mensing , Sandeep Dutta , Daniel E. Cohen , Thomas J. Podsadecki , Scott C. Brun , Walid M. Awni , Emily O. Dumas , Cheri E. Klein
Abstract: The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to a subject an effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), and an inhibitor of cytochrome P450 (e.g., ritonavir).
-
公开(公告)号：US20130102526A1
公开(公告)日：2013-04-25
申请号：US13656012
申请日：2012-10-19
Applicant: ABBVIE INC.
Inventor： Barry M. Bernstein , Rajeev M. Menon , Amit Khatri , Sven Mensing , Sandeep Dutta , Daniel E. Cohen , Thomas J. Podsadecki , Scott C. Brun , Walid M. Awni , Emily O. Dumas , Cheri E. Klein
IPC: A61K38/07 , A61P31/14 , A61K31/7068 , A61K31/7072 , A61K38/06
CPC classification number: A61K38/07 , A61K31/4025 , A61K31/4178 , A61K31/4196 , A61K31/427 , A61K31/4709 , A61K31/4725 , A61K31/473 , A61K31/501 , A61K31/513 , A61K31/5377 , A61K31/7072 , A61K38/05 , A61K45/06 , A61K2300/00
Abstract: The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to a subject an effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), and an inhibitor of cytochrome P450 (e.g., ritonavir).
-
-
-
-
-
-
-
Search Results
38
records
(took 0.036 seconds)
